Vericel Corp financial data

Symbol
VCEL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
64 Sidney St., Cambridge, MA
State of incorporation
MI
Fiscal year end
December 31
Former names
AASTROM BIOSCIENCES INC (to 11/14/2014)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 468 % -12.1%
Quick Ratio 34.2 % -18.5%
Debt-to-equity 53.9 % +12.7%
Return On Equity 1.48 %
Return On Assets 0.96 %
Operating Margin -0.54 % +92.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.4M shares +3.42%
Common Stock, Shares, Outstanding 49.3M shares +3.32%
Entity Public Float 1.77B USD +50.6%
Common Stock, Value, Issued 670M USD +7.85%
Weighted Average Number of Shares Outstanding, Basic 49.1M shares +3.01%
Weighted Average Number of Shares Outstanding, Diluted 49.1M shares +3.01%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 227M USD +22.5%
Revenue from Contract with Customer, Excluding Assessed Tax 227M USD +22.5%
Research and Development Expense 24.8M USD +15.8%
Operating Income (Loss) -1.23M USD +90.6%
Nonoperating Income (Expense) 5.88M USD +79.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -901K USD +77.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 3.55M USD +75.4%
Earnings Per Share, Basic 0.08 USD/shares +75%
Earnings Per Share, Diluted 0.08 USD/shares +75%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 53.7M USD -11.2%
Accounts Receivable, after Allowance for Credit Loss, Current 48.5M USD +22%
Inventory, Net 15.8M USD +24.8%
Other Assets, Current 7.88M USD +45.2%
Assets, Current 191M USD +2.31%
Operating Lease, Right-of-Use Asset 71.6M USD -2.36%
Other Assets, Noncurrent 610K USD -46.6%
Assets 390M USD +22.7%
Accounts Payable, Current 20.9M USD +38.8%
Employee-related Liabilities, Current 3.09M USD +17.4%
Accrued Liabilities, Current 14.3M USD +5.25%
Liabilities, Current 41.3M USD +15%
Operating Lease, Liability, Noncurrent 91.3M USD +17.5%
Other Liabilities, Noncurrent 243K USD +274%
Liabilities 133M USD +16.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 359K USD
Retained Earnings (Accumulated Deficit) -413M USD +0.85%
Stockholders' Equity Attributable to Parent 257M USD +26%
Liabilities and Equity 390M USD +22.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 7.2M USD -8.37%
Net Cash Provided by (Used in) Financing Activities 2.13M USD +1887%
Net Cash Provided by (Used in) Investing Activities -25.5M USD -1009%
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 49.3M shares +3.32%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.1M USD -250%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 70.4M USD -15.8%
Deferred Tax Assets, Valuation Allowance 49.8M USD +5.21%
Deferred Tax Assets, Gross 70.7M USD +17.5%
Operating Lease, Liability 85M USD
Depreciation 4.6M USD +15%
Payments to Acquire Property, Plant, and Equipment 14M USD +892%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 4.37M USD +92.3%
Lessee, Operating Lease, Liability, to be Paid 158M USD
Operating Lease, Liability, Current 6.12M USD -15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.7M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 10.7M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +18.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49.6M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 14M USD
Deferred Tax Assets, Operating Loss Carryforwards 4.51M USD -35.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.4M USD
Depreciation, Depletion and Amortization 1.38M USD +19%
Interest Expense 608K USD +23.3%